Phenylfuran-and phenylthiophene-alkanols and derivatives thereof

ABSTRACT

This invention relates to new heterocyclic compounds, and more particularly to new phenyl-heterocyclic-alkanol derivatives, which have anti-inflammatory, analgesic and antipyretic activity.

United States Patent [1 1 Hutton et a1. IMarch 20, 1973 (541 PHENYLFURAN-AND [58] Field of Search .....260/332.2 R, 332.3 R, 347.4,

PHENYLTI-IIOPHENE-ALKANOLS AND DERIVATIVES THEREOF inventors: Jonathan Hutton; Gilbert Joseph Stacey, both of Macclesfield. England Assignee: Imperial Chemical Industries Limited, London, England Filed: Aug. 26, 1971 Appl. No.: 175,402

Related US. Application Data Continuation-impart of Ser. No. 758,581, Sept. 9, 1968, Pat. No. 3,652,575.

US. Cl. ..260/332 .3 R, 26 0/332.2 R, 260/347.4, 260/347.8, 260/295 AM, 260/295 R,

Int. Cl ..A6lk 27/00, C07d 5/16, C07d 63/12 [56] I References Cited UNITED STATES PATENTS 3,652,575 3/1972 Hutton et a1. ..260/29.5

7 Primary Examiner-Henry R. Jiles Assistant Examiner-Cecilia M. S. Jaisle Attorney-Cushman, Darby & Cushman [5 7] ABSTRACT 2 Claims, No Drawings PHENYLFURAN-AND PHENYLTHlOPHENE- ALKANOLS AND DERIVATIVES THEREOF This application is a continuation-in-part of Ser. No. 758,581, filed Sept. 9, 1968, now US. Pat. No. 3,652,575, issued Mar. 28, 1972. 1

According to the invention we provide heterocyclic compounds of the formula:

wherein Het stands for a thiazole, isothiazole, oxazole, isoxazole, pyrrole, thiophen, furan, pyridine or pyrimidine ring, X stands for hydrogen or an alkyl or alkoxy radical of not more than three carbon atoms, Y stands for the phenyl radical, optionally substituted with not more than 2 halogen atoms, the same or different, or with the p-trifluoromethyl radical, and Z stands for a group of the formula:

wherein R and R, which may be the same or different, stand for hydrogen or an'alkyl radical of not more than three carbon atoms, and R stands for hydrogen, an alkyl radical of not more than four carbon atoms, an alkanoyl radical of not more than five carbon atoms, the benzoyl radical, a carboxybenzoyl radical, an alkanoyloxybenzoyl or dialkylcyclohexyloxyaikanoyl radical of not more than 12 carbon atoms, or theN- phenylcarbamoyl radical, or R stands for an acyl radical of the fonnula RR-"CR'R=CO-, wherein R stands for a phenyl, monoor di-halogenophenyl, or ptrifluoromethylphenyl radical, R stands for a thiazolyl, isothiazolyL'oxazolyl, isoxazolyl, pyrrolyl, thienyl, furyl, pyridyl, methylpyridyl, pyrimidyl or methoxypyrimidyl radical, and R and R have the meanings stated-above, and R and -CRR-CO- are linked to non-adjacent ring carbon atoms in R and wherein X,

Y and Z are linked to ring carbon atoms of Het in such a way that Y and Z are linked to non-adjacent ring carbon atoms thereof, and pharmaceutically acceptable salts thereof, but excluding 5-'(2-hydroxyethyl)-4- methyl-2-phenylthiazole, 3-(2-hydroxyethyl)-5-phenylisoxazole, and 5-(Z-hydroxyethyl)-4-methyl-2-phenyloxa'zole, and pharmaceutically acceptable salts thereof.

As stated above, in the compounds of this invention, Y and Z are linked to non-adjacentring carbon atoms in Het. It is to be understood that the corresponding radicals in the heterocyclic starting materials used in the processes of this invention are likewise linked to non-adjacent ring carbon atoms of Het. lt is further to be understood that, when R' and R are different, the compounds are racemic and they can be resolved by standard procedures to give the corresponding dand lisomers. Compounds wherein Y contains one or two substituent(s), as described above, constitute a preferred embodiment of the invention because, generally speaking, they are more active than the corresponding unsubstituted derivatives.

As a suitable value for X there may be mentioned, for example, hydrogen or the methyl or methoxy radical. The halogen substituent(s) in Y may be selected from, for example, fluorine, chlorine and bromine atoms.

As a suitable value for R or R there may be mentioned, for example, hydrogen or the methyl radical. As a suitable value for R there may be mentioned, for example, hydrogen or the methyl, acety-I, propionyl, benzoyl, o-carboxybenzoyl, o-acetoxybenzoyl, a-( 2- isopropyl-5-methyl-cyclohexyloxy)acetyl, 2-(4- chlorophenyl)thiazol-4-ylacetyl or N-phcnylcarbamoyl radical.

As suitable salts there may be mentioned non-toxic pharmaceu'tically-acceptable acid-addition salts, for example a hydrochloride or tartrate.

Preferred compounds of this invention are 4-(4- bromophenyl)-2-(2-hydroxyisopropyl)thiazole, 2-(4- chlorophenyl)-5-( 2-hydroxyisopropyl)-6-methylpyridine, and 2-(4-chlorophenyl)-5-(2-hydroxyethyl )thiophen.

According to a further feature of the invention we provide a process for the manufacture of the compounds of the invention wherein R? stands for hydrogen, and pharmaceutically-acceptable salts thereof, which comprises reducing a compound of the formula: v

'diethyl ether or tetrahydrofuran, optionally under'the influence of heat, Alternatively, the reduction may be 'carried out using an alkali metal borohydride in a diluent or solvent, for example ethanol or water, optionally under the,i nfluence ofheat.

According to a. further feature of the inventionwe provide a process for the manufacture of the compounds of the invention wherein R stands for an alkanoyl radical of not more than five carbon atoms, the benzoyl radical, a carboxybenzoyl radical, an alkanoyloxybenzoyl or dialkylcyclohexyloxyalkanoyl radical of not more than 12 carbon atoms, or the N- phenylcarbamoyl radical, or R stands for an acyl radical of the formula R-R -CR R CO, wherein R, R, R and R have themeanings stated above, and pharmaceutically acceptable salts thereof, which comprises acylating a compound of the formula:

Y-1 mc rum-0112011 wherein Het, X, Y, R and R have the meaningsstated lide may be carried out under the influence of heat. Alternatively, the acylation may be carried out using the appropriate carboxylic acid and dicyclohexylcarbodiimide in a diluent or solvent, for example tetrahydrofuran. in the case where R stands for the N-phenylcarbamoyl radical, the acylation may be carried out using phenyl isocyanate as the acylating agent, optionally in the presence of an inert diluent or solvent, for example benzene.

According to a further feature of the invention we provide a process for the manufacture of the compounds of the invention wherein R stands for an alkyl radical of not more than three carbon-atoms, and pharmaceutically acceptable salts thereof, whichcomprises alkylating the corresponding compound wherein R stands for hydrogen. The alkylation may be carried out by reacting the appropriate compound wherein R stands for hydrogen with an alkyl halide of not more than three carbon atoms, for example methyl iodide, in the presence of an alkali metal or alkali metal hydride, for example sodium or sodium hydride. The reaction may be carried out in a diluent or solvent, for example dimethyl sulphoxide.

According to a further feature of the invention we provide a process for the manufacture of the compound of the invention wherein R, R and R stand for hydrogen, and pharmaceutically acceptable salts thereof, which comprises reacting a Grignard reagent of the formula:

Y-Hat-Mg-Hal wherein, Het, X and Y have the meanings stated above and Hal stands for a chlorine, bromine or iodine atom, with ethylene oxide or an ethylene halogenohydrinand then hydrolyzing the resulting complex. The reaction involving the Grignard reagent may be carried out in a diluent or solvent, for example benzene.

It is to be understood that the starting materials used in the processes of this invention may be obtained by conventional methods.

According to a further feature of the invention we acid, flufenamic acid, ibufenac, or an anti-inflammatory steroid, for example prednisolone. Those compositions intended for oral administration may, in addition, optionally contain at least one anti-cholinergic agent,

for example homatropine methyl bromide, and/or an antacid, for example aluminum hydroxide. Those compositions designed for topical application may, in addition, optionally contain a vasodilating agent, for example tolazoline, or a vasoconstricting agent, for example adrenaline; a local 7 anaesthetic, for example amethocaine, or a counter-irritant, for example capsicum; and/or at least one agent chosen from the following classes of substances: antibacterial agents, which includes sulphonamides and antibiotics having antibacterial action, for example neomycin; anti-fungal agents, for example hydroxyquinoline; anti-histaminic agents, for example promethazine; and rubefacient agents, for example methyl nicotinate.

The invention is illustrated but not limited by the following Examples:

EXAMPLE 1 hydride (1.9g.) stirred in dry ether (70ml.). The mixleast one heterocyclic compound of the formula:

wherein Het, X, Y and Z have the meanings stated above, or a pharmaceutically acceptable salt thereof, and an inert, non-toxic, diluent or carrier.

The pharmaceutical compositions may, for example, be in the form of tablets, pills, capsules, suppositories, non-sterile aqueous or non-aqueous solutions or suspensions, sterile injectable aqueous or non-aqueous solutions or suspensions, creams, lotions, or ointments. These compositions may be obtained in conventional manner using conventional excipients. The compositions may optionally contain, in addition to at least one of the heterocyclic compounds which characterize this invention, at least one known agent having anti-inflammatory and/or analgesic activity, for example aspirin, paracetamol, codeine, chloroquine, phenylbutazone, oxyphenbutazone, indomethacin, mefenamic ture was then stirred and boiled gently under reflux for 1 hour. It was cooled to between 0 and 10C., and v water was added dropwise until no more reaction occurred. Additional water was added to permit easy separation of the ether layer. The mixture was,

EXAMPLE 2 Methyl 2-(4-chlorophenyl)thiazol-4-ylacetate (16g; m.p.72C.) was dissolved in warm dry ethanol (l25ml.), and sodium borohydride (8g.) was-added with stirring. The mixture was refluxed for 1 hour, and water (l25ml.) was then added dropwise to the wellstirred solution. The initial precipitate redissolved to leave a sticky residue which was separately dissolved in hot water (25ml.). This solution was added to the clear supernatant liquid. The whole clear mixture was cooled to 5-l0C., and water (225ml.) was added dropwise with vigorous stirring. The emulsion which appeared usually needed seeding with a little of .the productbefore it would readily solidify. The mixture was stirred at 5C. for 1 hour, and then filtered. The residual solid was pressed dry on the filter, and was then redissolved as far as possible in warmethanol (l25ml.). The clear solution was decanted from the sticky' insoluble residue. After cooling the clear solution to 5l0" C.,

' water (375ml.) was added dropwise with vigorous stirring to precipitate the product (again, seeding of the initial emulsion was usually necessary before the precipitate would solidify). The product was filtered off after the mixture had been stirred for one hour at 5C., and dried in vacuo at 35C. There was thus obtained 2- (4-chlorophenyl)-4-( 2-hydroxyethyl)thiazole, m.p.6666 .5 C.

EXAMPLE 3 ture was stirred at 5C. for 1 hour, filtered, and the solid residue was pressed dry onthe filter. The solid was redissolved as far as possible in warm ethanol (70ml.), and the clear solution was decanted from the sticky residue. After cooling the solution to 5-l0C., water (l 50ml.) was added dropwise with vigorousstirring to precipitate the product, which again usually required seeding before it would readily solidify. The

- mixture was stirred for one hour at 5C., filtered, and

the solid residue was dried in vacuo at 35C. There was thus obtained 2-(4-chlorophenyl)'-4-( 2-hydroxyethyl)- -methoxypyrimidine, m'.p.98C.

EXAMPLE 5 Methyl 2-(4-chlorophenyl)-6-methylpyrid-5- ylatetate (3.3g;- 75-76C.) was dissolved in wan'n dry ethanol (ml.), and sodium borohydride (l.6g.).was added. The mixture was heated to 60C., and then left the solid residue was dried in vacuo at 35C to give 2- (4 -chlorophenyl)-5-(2-h'ydroxyethyl)-4- methylthiazole, m.p.96C.

EXAMPLE 6 A vmixture of 2(4-chlorophenyl)-4-(2-hydroxyethyl)thiazole (0.48g.) and acetic anhydride (0.41 g.) washeated at 100C. for 18 hours. The mixture was dissolved in chloroform (5ml.), and the solution was succes'sively washed with water, saturated sodium bicarbonate solution, and water. The chloroform layer was dried with anhydrous magnesium sulphate, and the chloroform was distilled off at a reduced pressure to leave a white solid residue which was crystallized from hexane. There was thus obtained 4-'(2- acetoxyethyl)-2- (4-chlorophenyl)thiazole, m.p.50-5 2C.

EXAMPLE 7 A mixture of 2-(4-chlorophenyl)-4-(Z-hydroxyethyl)thiazole (4.8g.) and propionic anhydride (5.2g.) was heated at 100C. for 18 hours. The reaction mixture was dissolved in chloroform (50ml.), and the solution was successively washed with water, saturated stirring to cool during 18 hours. Water (25ml.) was added to the vigorously stirred reaction mixture, and the sticky residue was redissolved by warming the reaction mixture. After cooling to 5-l0C., more water was added dropwise with stirring until precipitation was complete. The mixture was stirred for 1 hour at 5C., and then filtered, and the solid residue was dissolved as far as possible in warm ethanol (20ml.). The mixture was filtered, the filtrate was cooled to 5C., andthe product was precipitated by the dropwise addition of water at 5-l0C. The mixture was filtered and the solid residue was dried in vacuo'v at 35C. There was thus obtained 2-(4-chlorophenyl)-5-(Z-hydroxyethyl)- 6-methylpyridine, m.p. 89.590C.

EXAMPLE 5 A mixture of ethyl 2-(4-chlorophenyl)-4-methylthiazol-S-ylacetate (l.57g.; m.p.57 C.), sodium borohydride (0.67g.) and anhydrous ethanol (22ml.) was refluxed for 2 hours. Water (25ml.) was added to the hot solution and, aftercooling, a sticky residue was deposited. The residue was separated by decantation and dissolved in a little hot water, and the solution was added to the clear mother liquor. The mixture was cooled to 10C. and water (25ml.) was added. The mixture was stirred at 10C. for 2 hours, and then filtered. The solid residue was dissolved as far as possible in warm ethanol (25ml.), and the mixture was filtered. The filtrate was cooled to. 10C. and water (35ml.) was sodium bicarbonate solution, and water. The chloroform layer was dried with anhydrous magnesium sulphate, and the chloroform distilled off at a reduced pressure to leave a white solid residue which was crystallized from hexane. There was thus obtained 2- (4-chlorophenyl)-4-(2-propionyloxyethyl)-thiazole,

EXAMPLE'8 A mixture of dicyclohexylcarbodiimide (4.12g.) and 2-(4-chlorophenyl)thiazol-4-ylacetic acid (5.07g.) in anhydrous tetrahydrofuran (l0ml.) was stirred at 0C. for 30 minutes. 2-(4-Chlorophenyl)-4-(2-hydroxyethyl)thiazole (4.79g.) was dissolved in anhydrous tetrahydrofuran (l0ml.), and the solution was added dropwise with stirring to the above mixture at 0C. The

' resulting mixture was stirred at 0C. for a further 2 was EXAMPLE 9 A solution of 2-(4-chlorophenyl)-4-(2-hydroxyethyl)thiazole (3'g.) in dry benzene (25ml.) was added dropwise with stirring to a solution of phenyl isocyanate (1.48g.) in dry benzene (5ml.) at ambient temperature. The mixture was stirred at ambient temperature for 18 hours and then filtered. The solid residue 2-(4-chlorophenyl)-4-(Z-N-phenylcarbamoyloxv yethyl)thiazole, m.p. l 22-l 25C.

added dropwise. The resulting mixture was filtered and EXAMPLE l0 Ethyl 3-(4-chlorophenyl)isoxazol-S-ylacetate (2g; m.p.934C.), sodium borohydride (lg.) and dry ethanol (20ml.) were mixed and agitated for 16 hours. The mixture was poured into 50 parts of water, made acid with hydrochloric acid, and the resulting mixture was filtered. The solid residue was crystallized from a mixture of benzene and petroleum ether (boiling point 60-80C.) to give 3-(4-chlorophenyl)-5 Z-hydroxyethyl)isoxazole, m.p.59-60C.

EXAMPLE 1 i In a similar manner to that described in Example 2 the following compounds were obtained from the appropriate starting materials (cyclohexane was used as the solvent for crystallizing products, except where otherwise stated):- 4-(4-bromophenyl )-2-(2-hydroxyethyl)thiazole, m.p.l07-l09C. 2-(4-bromophenyl)- 4-(2hydroxyisopropyl)thiazole, -H 3 ,400cm.-

absorption at no C=O absorption at l,730cm.". hydroxyisopropyl)thiazole, m.p.73C. bromophenyl)-4-(2-hydroxy-t-butyl)thiazole, m.p.95C. 4-(4-bromophenyl)-2-(2-hydroxy-t-butyl)thiazole, m.p.76.SC. 2-(2,4-dichlorophenyl) 4-(2- hydroxyisopropyl)thiazole, 0-H absorption at 3,400c mr i."

absorption at l,745cm.". 2-(2,4-dichlorophenyl) 4-( 2- hydtoxyisopropyl)thiazole,- 0-H absorption absorption at l,750cm.. 4-(4-chlorophenyl)-2-(2- hydroxy-t-butyl)thiazole, m.p.55-56C. 2-(4- chlorophenyl)-5-(2-hydroxyethyl)thiazole, m.p.85-86 C.' 2-(4-chlorophenyl)-5-(2-hydroxyisopropyl)-6- methylpyridine, m.p.1 l0l I 1C. 2-(4-chlorophenyl)- 4-(2-hydroxyethyl)oxazole, m.p.89-90C. chlorophenyl)-4 (2-hydroxyethyl)pyrrole, m.p.l06-l 07C. 3-(4-chlorophenyl)-5-(2-hydroxy-t-butyl)isoxazole, m.p. 78-79C.

' EXAMPLE 12 To a solution of 2-(4-chlorophenyl)-4-(2-hydroxyethyl)thiazole (l.2g.) in dry dimethyl sulphoxide ml.) was added a 50 percent dispersion of sodium hydride in paraffin oil.(0.25g.). The'mixture was heated at 40C. for [5 minutes and cooled to room temperature. Methyl iodide (0.7lg.) in dry dimethyl sulphoxide (2ml.) was added dropwise with vigorous stirring. The reaction mixture was poured into water (l50ml.) and extracted with ether (3 X ml.). The ethereal extract was dried over anhydrous magnesium sulfate, and the solvent evaporated to give a pale yellow oil which was chromatographed on silica gel (100g.) using ether/hexane mixtures from 3, to 50 percent.

I There. was thus obtained as the main fraction 2-(4- 4-(4-bromophenyl)-2-( 2- chlorophenyl)-4-(2-methoxyethyl)thiazole, m.p.48-5 1C.

EXAMPLE 13 Acetylsalicylyl chloride (7.l5g.), dissolved in dry benzene (25ml.), was added with stirring and cooling below 20C. to a solution of 2-(4-chlorophenyl)-4-(2- hydroxyethyl)thiazole (6.3g.) and triethylamine (7ml.)

' in dry benzene (l00ml.). The mixture was stirred and refluxed overnight, diluted with chloroform and the organic phase washed with saturated'sodium bicarbonate magnesium solution and dried with anhydrous sulphate. Distillation of the organic solvent under reduced pressure left a red solid which was crystallized from a small volume of ethanol. There was thus obtained 4-(2-acetylsalicyclyloxyethyl)-2-( 4-chlorophenyl)thiazole, m.p.99-lO0C.

In a similar manner the following compound was obtained from the appropriate starting materials: 4-(4- bromophenyl )-2-[ 2-'/a-( 2-isopropyl-S -m ethylcyclohexyl-oxy )acetoxy/isopropyl]thiazole, strong absorptiomat 1,750cmf and no -O-H absorption at EXAMPLE l4 4-(4-Bromophenyl)-2-( 2-hydroxyisopropyl)thiazole (11.92g.) was dissolved in dry pyridine (64ml.), and to the solution was added powdered phthalic anhydride (6.23.). The mixture was stirred overnight at room temperature and then on thesteam bath for one hour. The

. reaction mixture was poured into a mixture of concenextracts were dried over anhydrous magnesium sulphate. The solvent was evaporated under reduced pressure, and there was thus obtained the half phthalate ester of 4-(4-bromophenyl)-2 (2-hydroxyisopropyl)thiazole, carboxylic type infra red absorptions between 2,600 and 3,400 cm. and at 1680cm.. No alcoholicO-H absorption at 3,350cm.".

EXAMPLE 1 5 To a solution of 2-(4-chlorophenyl)thiazol-4-ylacetic acid ig) in tetrahydrofuran (28ml.) was added an excess (5 molar) of lithium aluminum hydride. After being stirred at room temperature for half an hour, the mixture was refluxed overnight, and then poured into an excess of dilute hydrochloric acid.The resulting clear solution was made alkaline with saturated sodium bicarbonate solution and extracted with ether (3 X 'l0ml.). The combined ethereal extracts were dried over anhydrous magnesium sulphate, and the solvent The combined chloroform extracts were.

evaporated to leave a semi-solid residue. This was crystallized from cyclohexane to yield 2-(4- chlorophenyl)-4-(2-hydroxyethyl)-thiazole, m.p.66-66.5C.

EXAMPLE 16 A solution of 2-bromo-S-(4-chlorophenyl)thiophen (6.2g.) in dry ether (30ml.) was added with stirring to a suspension of magnesium turnings (0.55g.) in ether 50ml.) and saturated-sodium bicarbonate solution (50ml.), dried, and the solvent evaporated in vacuo. The solid residue was washed with cold petroleum ether (b.p.4060C.),'and crystallized from petroleum ether (b.p.l-l20"-C.) to yield 2-(4-chlorophen yl)-'5- (2-hydroxy-ethyl)thiophen, m.p.96-97C.

EXAMPLE 17 To a solution of 2-(4-chlorophenyl)thiazol-4-ylacetic trated hydrochloric acid. The resulting precipitate was filtered off, washed thoroughly with water, and then dried. The dry solid was dissolved in a small volume of diethyl ether, and the solution was put on a column of dry silica gel in a polythene tube (ca. 0.5 inch diameter X 24 inches). The column was eluted with chloroform (ca. l00ml.), and then cut into 2 inches segments. Each segment was separately extracted with chloroform (l00ml.), and the location of the desired product was determined'by thin layer chromatography (ca. lp.l. of

each extract was placed on a silica gel TLC plate, elutetrahydrofuran 15ml.) was added dropwise at C. a I

solution of ethyl chloroformate (0.01 mole) in tetrahydrofuran (5ml.) over minutes. After stirring for 30 minutes at 5C., the triethylamine hydrochloride was filtered off. The filtrate comprised a solution of the mixed anhydride of ethoxyformic acid and 2-(4-chlorophenyl)-thiazol-4-ylacetic acid. This solution was added dropwise to an aqueous solution of sodium borohydride (0.03 mole in 10ml. water) at l0l 5C., and the mixture was stirred at this temperature for 1 hour. The temperature of the mixture was then raised to 30-35C. until thin layer chromatography indicated that the reduction was complete. The reaction mixture was poured into water (l00ml.), acidified to pH 4 with hydrochloric acid, and extracted with ether (3 X ml.). The ethereal extract was dried with anhydrous magnesium sulphate, and the solvent was evaporated to leave a residue which was chromatographed on silica gel using an eluting solvent from 3 to 40 percent of acetone in cyclohexane. There was thus obtained 2-(4-chlorophenyl)-4-(2-hydroxyethyl)thiazole, m.p.66-66.5C.

EXAMPLEIB Micronized 2-(4-chlorophenyl)-4-(2-hydroxyethyl)- thiazole (l00mg./tablet), lactose (20mg./tablet), starch (3 l .6mg./tablet), calcium phosphate (60mg./tablet) and polyvinylpyrrolidone (125mg. as a 5 percent. aqueous solution/tablet) were milled together, and the mixture was made into tablets with magnesium stearate (2.15mg./tablet) as a lubricant.

EXAMPLE l9 Methyl 2-(4-chlorophenyl)fur-Z-ylacetate (0.90g.) was dissolved in dry ethanol (l0ml.), and sodium borohydride (0.46g.) was added during 5 minutes. The mixture was refluxed for one hour, allowed to cool, poured into water, and acidified to pH 1 with concention was by means of 25% v/v ethyl acetate in benzene, and location by ultraviolet radiation, 254mg). The appropriate extracts were evaporated to dryness at 50 C. in vacuo, the solid residue was washed with a small volume of petroleum ether (b.p.40-60C.), and then dried in vacuo. There was thus obtained 2-(4- chlorophenyl)-5-(2-hydroxyethyl)furan, m.p.7274 C.

The heterocyclic compounds of this invention are active in the following procedure which is standard in the art for testing for anti-inflammatory activity (Newbould, Brit. J. Pharmacol. Chemotherap., 1963, 21, 127136).

Adjuvant Induced Arthritis in Rats When 0.05ml. of a fine suspension containing 5mg./ml. of dead tubercle bacilli in liquid paraffin is injected into the foot-pad of a rat, a primary swelling is produced. This swelling increases in size for three days, and then diminishes slightly until the seventh day, when further swelling occurs. Ten days after the injection, inflamed lesions (which are called secondary lesions) appear in areas of the body which are remote from the actual site of injection; particularly on the joints of the fore-paws, hind-paws and tail. Little further swelling of the feet or joints occurs after the thirteenth day (after the injection). These secondary lesions are considered to have arisen as a result of an immunological reaction involving constituents of the dead tubercle bacilli which became disseminated after injection.

The heterocyclic compounds of this invention have been tested for anti-inflammatory properties as follows:

Each rat in a group of 3 male rats (average weight ca. 200g.) was dosed orally with the test compound'(as an aqueous suspension), and, on the day after dosing, ari injection of dead tubercle bacilli was given as above. There was one control group of 3 rats (which received dead tubercle bacilli but no test compound) for every 5 groups of rats receiving test compounds. The test compound was then dosed orally each day until the 13th day after the injection of the dead tubercle bacilli. The thickness of the injected foot was measured 3 days after injection ahd 13 days after injection. The results were expressed as the percentage inhibition of the increase in thickness of the injected feet of the treated rats. The results obtained with a representative selection of the said heterocyclic compounds are shown in the following table (in the cases where the word Toxic appears, all the rats died before the thirteenth day after the injection). 4

Y-Het- Z The above results prove that the compounds in question exhibit anti-inflammatory activity in the rat,

inasmuch as the; prevent the development qfjnflammatron on Day and Day 13. Moreover, toxicity data cordingly, it is reasonable to conclude that the heterocyclic compounds of this invention possess analgesic and antipyretic activity.

The compounds of the invention are generically useful in the treatment of warm-blooded animals (including mammals) and, for this purpose, we recommend that said compounds be administered orally, for example in tablet or capsule form, and that the daily dosage be in the range of about 0.75mg. to 200mg. per kg. of host. in particular, when one of the said compounds is used in the treatment of man, we recommend that it be administered orally, for example in tablet or capsule form, at a total daily dose of 50mg. to 900mg.'of said compound per 70kg. man. I

What we claim is:

1. A compound selected from the group consisting of heterocyclic compounds of the formula:

wherein: Het is a member selected from the group consisting of thiophen and furan rings;

X is a member selected from the group consisting of hydrogen, alkyl of not more than three carbon atoms, and alkoxy of not more than three carbon atoms;

Y is a member selected from the group consisting of phenyl, monohalogenophenyl, dihalogenophenyl.

and p-trifluoromethyl-phenyl;

R and R are members selected from the group consisting of hydrogen and methyl;

R is a member selected from the group consisting of hydrogen, alkyl or not more than four carbon atoms, alkanoyl of not more than 5 carbon atoms and benzoyl; and wherein X, Y and CRR CH OR are linked to ring carbon atoms of Het in such a way that Y and CRR"CH OR are linked to non-adjacent ring carbon atoms of Het.

2. A compound as claimed in claim 1 which is 2-(4- chlorophenyl)-5-( 2-hydroxyethyl)thiophen. 

2. A compound as claimed in claim 1 which is 2-(4-chlorophenyl)-5-(2-hydroxyethyl)thiophen. 